Global Strategic Report
134 Pages; August 2018
Although long overlooked, exosomes are rapidly gaining momentum as a novel strategy for accessing the therapeutic effects of stem cells without the risks and difficulties of administering the cells to patients.
Although exosomes were discovered more than 30 years ago, it was not until recently that the scientific community began to give credit to exosomes for a range of promising traits. Ten years ago in 2006, there were only 76 articles published about exosomes on PubMed.gov. Today, there are more than 4,400 articles published about exosomes on PubMed.gov, of which approximately 25% were released in the past year.
When exosome publications are analyzed, U.S. authors have published approximately 40% of the articles and China comes in second place. When the term “exosome” is searched in the scientific literature, Dr. Susanne Gabrielsson from the Karolinska Institutet in Sweden is the leading author, with 37 articles.
When the term “extracellular vesicles” is searched, Unicyte AG, a regenerative medicine unit of Fresenius Medical Care, takes the lead. Headquartered in Switzerland, the company has published more than 100 papers on exosomes and extracellular vesicles in combination with Prof. Giovanni Camussi.
Exosome Industry Investments
On the venture capital front, there has also been a great deal of market activity.
In September 2018, Evox Therapeutics raised £35.5 million (USD $45.4 million) in Series B financing. According to Evox Therapeutics, an exosome therapeutics company based in the UK, leading investors included Redmile Group, GV (formerly Google Ventures), and Cowen Healthcare Investments. Evox had previously secured £10 million as part of a Series A seed financing.
In January 2016, Exosome Diagnostics closed $60 million in Series B financing, which it followed in July 2017 with $30 million in Series C financing. Similarly, Codiak Biosciences was launched in 2016 when the MD Anderson Cancer Center joined two venture capital firms to form the company with more than $80 million in series A and B financing. On November 29, 2017, Codiak BioSciences added another $76.5 million in Series C financing.
In May 2017, ExCoBio Inc. raised US $11 million in a Series A funding round.
Exosome and Extracellular Vesicle (EV) Clinical Trials
Furthermore, Aegle announced in May 2018 that it will be the first extracellular vesicle (EV) company to be cleared by the FDA to enter clinical trials in humans. The FDA cleared Aegle’s IND application to initiate a trial in severe second degree burn patients. The company plans to launch a Phase 1/2a clinical trial of its lead product AGLE-102 in late 2018.
Companies leading the charge in the area of exosome therapeutics include Anjarium Biosciences, Capricor Therapeutics, Codiak Biosciences, Creative Medical Technology Holdings, Everkine Corporation, Evox Therapeutics, Exogenus Therapeutics, Kimera Labs, ReNeuron, and Unicyte AG, a subsidiary of Fresenius Medical Care.
Numerous life science companies have also launched tools and systems to support exosome research, including Beckman Coulter, Exiqon, System Biosciences (SBI), Lonza, Thermo Fisher, Qiagen, ZenBio, and more. In particular, Lonza made aggressive investments in the sector through its May 2017 acquisition of HansaBioMed Life Sciences and investment into Exosomics.
Similarly, techniques for large-scale clinical-grade manufacture of stem cell exosomes is becoming a focal point within the industry, as highlighted by a recent partnership between RoosterBio and Exopharm, as well as Lonza’s strategic acquisitions. VivaZome Therapeutics was also awarded a grant of $2.18M by the Australian government to support an exosome manufacturing project.
Exosome Market Forces
Exosome-related technologies have been developing rapidly over the past few years and substantial growth is expected for the market as they get integrated into the fields of liquid biopsy, precision medicine and regenerative medicine. In particular, cancer derived exosomes influence the invasive potential of cells by regulating angiogenesis, metastasis, and immunity, making them an extremely useful source of biomarkers for use in cancer detection, diagnosis, and therapeutic selection.
While exosomes derived from multiple stem cell types are being explored, mesenchymal stem cell (MSC) derived exosomes are best represented within the scientific literature and global patent activity.
To characterize this rapidly forming marketplace, BioInformant has released a 134-page market report that explores growing demand for exosome therapeutics, diagnostics, research tools, consumer care products, and manufacturing technologies. It also reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials, and present social analytics from Google Trends and Google Adwords.
Claim it to:
- Get educated about the rapidly evolving exosome market
- Identify opportunities for exosome product development
- Reveal the identities of competitors developing exosome products, diagnostics, and therapeutics
- Access market size determinations, market segmentation, and 5-year projections through 2022
- Determine company strategy or purse external funding from investors
- Make smarter decisions, faster
Companies Mentioned Include:
- Aegle Therapeutics
- Anjarium Biosciences
- Avalon GloboCare Corp.
- Beckman Coulter
- Capricor Therapeutics
- Cavadis B.V.
- Cell Guidance Systems
- Codiak Biosciences
- CosmoBio USA
- Creative Medical Technologies Holdings
- ExoCoBio Inc.
- Exerkine Corporation
- Exosome Diagnostics
- Evox Therapeutics
- Exogenus Therapeutics
- Exosome Sciences
- Exosomics Siena SpA
- Exostemtech Co. Ltd.
- Exovita Biosciences
- Galen Lab Supplies
- Guangzhou Selaira Stem Cell Technology Co., Ltd
- HansaBioMed Life Sciences
- iZon Science
- Kimera Labs
- Miltenyi Biotec
- Norgen Biotek
- Unicyte AG
View Table of Contents: Market for Stem Cell Exosomes
As the first and only market research firm to specialize in the stem cell industry, BioInformant research has been cited by the Wall Street Journal, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.